- Home
- CAVA vs VTRS Comparison
CAVA vs VTRS Comparison
Compare CAVA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- VTRS
- Stock Information
- Founded
- CAVA 2006
- VTRS 1961
- Country
- CAVA United States
- VTRS United States
- Employees
- CAVA N/A
- VTRS N/A
- Industry
- CAVA Restaurants
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- CAVA Consumer Discretionary
- VTRS Health Care
- Exchange
- CAVA Nasdaq
- VTRS Nasdaq
- Market Cap
- CAVA 9.7B
- VTRS 10.6B
- IPO Year
- CAVA 2023
- VTRS N/A
- Fundamental
- Price
- CAVA $86.98
- VTRS $9.33
- Analyst Decision
- CAVA Buy
- VTRS Hold
- Analyst Count
- CAVA 15
- VTRS 5
- Target Price
- CAVA $115.87
- VTRS $10.40
- AVG Volume (30 Days)
- CAVA 4.4M
- VTRS 11.7M
- Earning Date
- CAVA 08-21-2025
- VTRS 08-07-2025
- Dividend Yield
- CAVA N/A
- VTRS 5.15%
- EPS Growth
- CAVA 274.67
- VTRS N/A
- EPS
- CAVA 1.20
- VTRS N/A
- Revenue
- CAVA $1,036,533,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- CAVA $26.28
- VTRS N/A
- Revenue Next Year
- CAVA $21.53
- VTRS $1.85
- P/E Ratio
- CAVA $72.14
- VTRS N/A
- Revenue Growth
- CAVA 32.11
- VTRS N/A
- 52 Week Low
- CAVA $70.00
- VTRS $6.85
- 52 Week High
- CAVA $172.43
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- CAVA 63.27
- VTRS 62.08
- Support Level
- CAVA $72.36
- VTRS $8.88
- Resistance Level
- CAVA $85.24
- VTRS $9.40
- Average True Range (ATR)
- CAVA 3.70
- VTRS 0.22
- MACD
- CAVA 1.65
- VTRS 0.03
- Stochastic Oscillator
- CAVA 94.31
- VTRS 89.19
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.